Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
Somatic mutations in PIK3CA (encoding a class I phosphoinositide 3 kinase (PI3K) subunit) modulate PI3K signalling to influence tumour behaviour and occur in up to 40% of breast cancers. Inhibitors of PI3K signalling are entering clinical trials, but the impact of PIKC3A mutation on tumour response...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2010-04, Vol.120 (2), p.461-467 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 467 |
|---|---|
| container_issue | 2 |
| container_start_page | 461 |
| container_title | Breast cancer research and treatment |
| container_volume | 120 |
| creator | Board, Ruth E Wardley, Andrew M Dixon, J. Michael Armstrong, Anne C Howell, Sacha Renshaw, Lorna Donald, Emma Greystoke, Alastair Ranson, Malcolm Hughes, Andrew Dive, Caroline |
| description | Somatic mutations in PIK3CA (encoding a class I phosphoinositide 3 kinase (PI3K) subunit) modulate PI3K signalling to influence tumour behaviour and occur in up to 40% of breast cancers. Inhibitors of PI3K signalling are entering clinical trials, but the impact of PIKC3A mutation on tumour response has yet to be clarified. This study investigated the potential utility of circulating free DNA (cfDNA) as a source for PIK3CA mutation detection in patients with breast cancer. cfDNA extracted (QIAamp Virus spin kit) from blood and matched archival tumour from 46 patients with metastatic breast cancer and 30 patients with localised, operable breast cancer was assessed for hotspot PIK3CA mutations using Amplification Refractory Mutation System (ARMS™) allele-specific PCR and Scorpion probes. PIK3CA mutations were detected in 13/46 (28%) plasma-derived and 10/46 (21%) serum-derived cfDNA samples from metastatic breast cancer patients. In 41 cases with matched tumour and plasma-derived cfDNA data, concordance (same mutation status in plasma and tumour) was 95%. Where a PIK3CA mutation was present in tumour, the ‘pick up' in plasma-derived cfDNA was 80%. PIK3CA mutations were present in tumours from 14/30 (47%) localised breast cancers, but no PIK3CA mutations were detected in matched cfDNA. These data demonstrate feasibility and potential utility of cfDNA for PIK3CA mutation detection in patients with metastatic breast cancer. Studies are underway to qualify PIK3CA mutation in cfDNA as a predictive biomarker allowing patient stratification in clinical trials of mechanism-based therapeutics that target PI3K signalling pathways. |
| doi_str_mv | 10.1007/s10549-010-0747-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_745900313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A356352748</galeid><sourcerecordid>A356352748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-e760ab855d1afed2a3c8e4b091f22f2e2b5b76ca0b5629cc3ae5fdf3d55662193</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEokvhB3CBCAScUsZ2bMfH1ZaPigqQaM-W44x3UyXx1k6E-Pc4ZKEUIZAPll8_74zmI8seEzghAPJ1JMBLVQCBAmQpC3UnWxEuWSEpkXezFRAhC1GBOMoexHgFAEqCup8d0WSRlSKr7OIUR7Rj64fcu_zz2Qe2Wef9NJpZink75LYNdurSe9jmLiDmpx_Xs75PEg5jzL-24y6vA5o45tYMFsPD7J4zXcRHh_s4u3z75mLzvjj_9O5ssz4vLFdyLFAKMHXFeUOMw4YaZissa1DEUeoo0prXUlgDNRdUWcsMctc41nAuBCWKHWevlrj74K8njKPu22ix68yAfopallwBMML-TzLGytQ0nshnf5BXfgpDKkNTQssKVCkS9HyBtqZD3Q7Oj8HYOaReMy4Yp7KsEnXyFyqdBvvW-gFdm_Rbhpe_GXZounEXfTf9mMVtkCygDT7GgE7vQ9ub8E0T0PNq6GU1dJqznldDz816cihsqntsfjl-7kICXhwAE63pXEizbOMNR3lFKZmT04WL6WvYYrjp0L-yP11MznhttiEFvvySUjMgFZGUl-w7vS_Vgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212480946</pqid></control><display><type>article</type><title>Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Board, Ruth E ; Wardley, Andrew M ; Dixon, J. Michael ; Armstrong, Anne C ; Howell, Sacha ; Renshaw, Lorna ; Donald, Emma ; Greystoke, Alastair ; Ranson, Malcolm ; Hughes, Andrew ; Dive, Caroline</creator><creatorcontrib>Board, Ruth E ; Wardley, Andrew M ; Dixon, J. Michael ; Armstrong, Anne C ; Howell, Sacha ; Renshaw, Lorna ; Donald, Emma ; Greystoke, Alastair ; Ranson, Malcolm ; Hughes, Andrew ; Dive, Caroline</creatorcontrib><description>Somatic mutations in PIK3CA (encoding a class I phosphoinositide 3 kinase (PI3K) subunit) modulate PI3K signalling to influence tumour behaviour and occur in up to 40% of breast cancers. Inhibitors of PI3K signalling are entering clinical trials, but the impact of PIKC3A mutation on tumour response has yet to be clarified. This study investigated the potential utility of circulating free DNA (cfDNA) as a source for PIK3CA mutation detection in patients with breast cancer. cfDNA extracted (QIAamp Virus spin kit) from blood and matched archival tumour from 46 patients with metastatic breast cancer and 30 patients with localised, operable breast cancer was assessed for hotspot PIK3CA mutations using Amplification Refractory Mutation System (ARMS™) allele-specific PCR and Scorpion probes. PIK3CA mutations were detected in 13/46 (28%) plasma-derived and 10/46 (21%) serum-derived cfDNA samples from metastatic breast cancer patients. In 41 cases with matched tumour and plasma-derived cfDNA data, concordance (same mutation status in plasma and tumour) was 95%. Where a PIK3CA mutation was present in tumour, the ‘pick up' in plasma-derived cfDNA was 80%. PIK3CA mutations were present in tumours from 14/30 (47%) localised breast cancers, but no PIK3CA mutations were detected in matched cfDNA. These data demonstrate feasibility and potential utility of cfDNA for PIK3CA mutation detection in patients with metastatic breast cancer. Studies are underway to qualify PIK3CA mutation in cfDNA as a predictive biomarker allowing patient stratification in clinical trials of mechanism-based therapeutics that target PI3K signalling pathways.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-010-0747-9</identifier><identifier>PMID: 20107891</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Boston : Springer US</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Biomarkers ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - genetics ; Cancer ; Cancer patients ; Cancer research ; Cancer therapies ; Care and treatment ; Class I Phosphatidylinositol 3-Kinases ; Clinical Trial ; Clinical trials ; Deoxyribonucleic acid ; DNA ; DNA - blood ; DNA - genetics ; DNA Mutational Analysis ; Female ; Genes ; Genetic aspects ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Oncology ; Phosphatidylinositol 3-Kinases - genetics ; Tumors</subject><ispartof>Breast cancer research and treatment, 2010-04, Vol.120 (2), p.461-467</ispartof><rights>Springer Science+Business Media, LLC. 2010</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2010 Springer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-e760ab855d1afed2a3c8e4b091f22f2e2b5b76ca0b5629cc3ae5fdf3d55662193</citedby><cites>FETCH-LOGICAL-c597t-e760ab855d1afed2a3c8e4b091f22f2e2b5b76ca0b5629cc3ae5fdf3d55662193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-010-0747-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-010-0747-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22582218$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20107891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Board, Ruth E</creatorcontrib><creatorcontrib>Wardley, Andrew M</creatorcontrib><creatorcontrib>Dixon, J. Michael</creatorcontrib><creatorcontrib>Armstrong, Anne C</creatorcontrib><creatorcontrib>Howell, Sacha</creatorcontrib><creatorcontrib>Renshaw, Lorna</creatorcontrib><creatorcontrib>Donald, Emma</creatorcontrib><creatorcontrib>Greystoke, Alastair</creatorcontrib><creatorcontrib>Ranson, Malcolm</creatorcontrib><creatorcontrib>Hughes, Andrew</creatorcontrib><creatorcontrib>Dive, Caroline</creatorcontrib><title>Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Somatic mutations in PIK3CA (encoding a class I phosphoinositide 3 kinase (PI3K) subunit) modulate PI3K signalling to influence tumour behaviour and occur in up to 40% of breast cancers. Inhibitors of PI3K signalling are entering clinical trials, but the impact of PIKC3A mutation on tumour response has yet to be clarified. This study investigated the potential utility of circulating free DNA (cfDNA) as a source for PIK3CA mutation detection in patients with breast cancer. cfDNA extracted (QIAamp Virus spin kit) from blood and matched archival tumour from 46 patients with metastatic breast cancer and 30 patients with localised, operable breast cancer was assessed for hotspot PIK3CA mutations using Amplification Refractory Mutation System (ARMS™) allele-specific PCR and Scorpion probes. PIK3CA mutations were detected in 13/46 (28%) plasma-derived and 10/46 (21%) serum-derived cfDNA samples from metastatic breast cancer patients. In 41 cases with matched tumour and plasma-derived cfDNA data, concordance (same mutation status in plasma and tumour) was 95%. Where a PIK3CA mutation was present in tumour, the ‘pick up' in plasma-derived cfDNA was 80%. PIK3CA mutations were present in tumours from 14/30 (47%) localised breast cancers, but no PIK3CA mutations were detected in matched cfDNA. These data demonstrate feasibility and potential utility of cfDNA for PIK3CA mutation detection in patients with metastatic breast cancer. Studies are underway to qualify PIK3CA mutation in cfDNA as a predictive biomarker allowing patient stratification in clinical trials of mechanism-based therapeutics that target PI3K signalling pathways.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - genetics</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Class I Phosphatidylinositol 3-Kinases</subject><subject>Clinical Trial</subject><subject>Clinical trials</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA - blood</subject><subject>DNA - genetics</subject><subject>DNA Mutational Analysis</subject><subject>Female</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Phosphatidylinositol 3-Kinases - genetics</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhiMEokvhB3CBCAScUsZ2bMfH1ZaPigqQaM-W44x3UyXx1k6E-Pc4ZKEUIZAPll8_74zmI8seEzghAPJ1JMBLVQCBAmQpC3UnWxEuWSEpkXezFRAhC1GBOMoexHgFAEqCup8d0WSRlSKr7OIUR7Rj64fcu_zz2Qe2Wef9NJpZink75LYNdurSe9jmLiDmpx_Xs75PEg5jzL-24y6vA5o45tYMFsPD7J4zXcRHh_s4u3z75mLzvjj_9O5ssz4vLFdyLFAKMHXFeUOMw4YaZissa1DEUeoo0prXUlgDNRdUWcsMctc41nAuBCWKHWevlrj74K8njKPu22ix68yAfopallwBMML-TzLGytQ0nshnf5BXfgpDKkNTQssKVCkS9HyBtqZD3Q7Oj8HYOaReMy4Yp7KsEnXyFyqdBvvW-gFdm_Rbhpe_GXZounEXfTf9mMVtkCygDT7GgE7vQ9ub8E0T0PNq6GU1dJqznldDz816cihsqntsfjl-7kICXhwAE63pXEizbOMNR3lFKZmT04WL6WvYYrjp0L-yP11MznhttiEFvvySUjMgFZGUl-w7vS_Vgg</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Board, Ruth E</creator><creator>Wardley, Andrew M</creator><creator>Dixon, J. Michael</creator><creator>Armstrong, Anne C</creator><creator>Howell, Sacha</creator><creator>Renshaw, Lorna</creator><creator>Donald, Emma</creator><creator>Greystoke, Alastair</creator><creator>Ranson, Malcolm</creator><creator>Hughes, Andrew</creator><creator>Dive, Caroline</creator><general>Boston : Springer US</general><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TM</scope><scope>7U9</scope></search><sort><creationdate>20100401</creationdate><title>Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer</title><author>Board, Ruth E ; Wardley, Andrew M ; Dixon, J. Michael ; Armstrong, Anne C ; Howell, Sacha ; Renshaw, Lorna ; Donald, Emma ; Greystoke, Alastair ; Ranson, Malcolm ; Hughes, Andrew ; Dive, Caroline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-e760ab855d1afed2a3c8e4b091f22f2e2b5b76ca0b5629cc3ae5fdf3d55662193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - genetics</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Class I Phosphatidylinositol 3-Kinases</topic><topic>Clinical Trial</topic><topic>Clinical trials</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA - blood</topic><topic>DNA - genetics</topic><topic>DNA Mutational Analysis</topic><topic>Female</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Phosphatidylinositol 3-Kinases - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Board, Ruth E</creatorcontrib><creatorcontrib>Wardley, Andrew M</creatorcontrib><creatorcontrib>Dixon, J. Michael</creatorcontrib><creatorcontrib>Armstrong, Anne C</creatorcontrib><creatorcontrib>Howell, Sacha</creatorcontrib><creatorcontrib>Renshaw, Lorna</creatorcontrib><creatorcontrib>Donald, Emma</creatorcontrib><creatorcontrib>Greystoke, Alastair</creatorcontrib><creatorcontrib>Ranson, Malcolm</creatorcontrib><creatorcontrib>Hughes, Andrew</creatorcontrib><creatorcontrib>Dive, Caroline</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Board, Ruth E</au><au>Wardley, Andrew M</au><au>Dixon, J. Michael</au><au>Armstrong, Anne C</au><au>Howell, Sacha</au><au>Renshaw, Lorna</au><au>Donald, Emma</au><au>Greystoke, Alastair</au><au>Ranson, Malcolm</au><au>Hughes, Andrew</au><au>Dive, Caroline</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>120</volume><issue>2</issue><spage>461</spage><epage>467</epage><pages>461-467</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Somatic mutations in PIK3CA (encoding a class I phosphoinositide 3 kinase (PI3K) subunit) modulate PI3K signalling to influence tumour behaviour and occur in up to 40% of breast cancers. Inhibitors of PI3K signalling are entering clinical trials, but the impact of PIKC3A mutation on tumour response has yet to be clarified. This study investigated the potential utility of circulating free DNA (cfDNA) as a source for PIK3CA mutation detection in patients with breast cancer. cfDNA extracted (QIAamp Virus spin kit) from blood and matched archival tumour from 46 patients with metastatic breast cancer and 30 patients with localised, operable breast cancer was assessed for hotspot PIK3CA mutations using Amplification Refractory Mutation System (ARMS™) allele-specific PCR and Scorpion probes. PIK3CA mutations were detected in 13/46 (28%) plasma-derived and 10/46 (21%) serum-derived cfDNA samples from metastatic breast cancer patients. In 41 cases with matched tumour and plasma-derived cfDNA data, concordance (same mutation status in plasma and tumour) was 95%. Where a PIK3CA mutation was present in tumour, the ‘pick up' in plasma-derived cfDNA was 80%. PIK3CA mutations were present in tumours from 14/30 (47%) localised breast cancers, but no PIK3CA mutations were detected in matched cfDNA. These data demonstrate feasibility and potential utility of cfDNA for PIK3CA mutation detection in patients with metastatic breast cancer. Studies are underway to qualify PIK3CA mutation in cfDNA as a predictive biomarker allowing patient stratification in clinical trials of mechanism-based therapeutics that target PI3K signalling pathways.</abstract><cop>Boston</cop><pub>Boston : Springer US</pub><pmid>20107891</pmid><doi>10.1007/s10549-010-0747-9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2010-04, Vol.120 (2), p.461-467 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_745900313 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Biological and medical sciences Biomarkers Breast cancer Breast Neoplasms - blood Breast Neoplasms - genetics Cancer Cancer patients Cancer research Cancer therapies Care and treatment Class I Phosphatidylinositol 3-Kinases Clinical Trial Clinical trials Deoxyribonucleic acid DNA DNA - blood DNA - genetics DNA Mutational Analysis Female Genes Genetic aspects Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Medicine Medicine & Public Health Middle Aged Mutation Oncology Phosphatidylinositol 3-Kinases - genetics Tumors |
| title | Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T19%3A53%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20of%20PIK3CA%20mutations%20in%20circulating%20free%20DNA%20in%20patients%20with%20breast%20cancer&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Board,%20Ruth%20E&rft.date=2010-04-01&rft.volume=120&rft.issue=2&rft.spage=461&rft.epage=467&rft.pages=461-467&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-010-0747-9&rft_dat=%3Cgale_proqu%3EA356352748%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212480946&rft_id=info:pmid/20107891&rft_galeid=A356352748&rfr_iscdi=true |